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Alpha-I-antitrypsin deficiency is a common genetic defect associated with the development of severe and rapidly 
progressive lung disease. This study was undertaken to determine whether respiratory physicians manage patients 
with alpha-1-antitrypsin (AAT) deficiency differently from patients with chronic obstructive pulmonary disease 
(COPD) without alpha-I-antitrypsin deficiency. In addition we obtained physicians’ views on who should be tested 
for AAT deficiency. 
A questionnaire was administered to 88 respiratory physicians based throughout the U.K. (44 in teaching 
hospitals). The main outcome measures were pulmonary function tests, radiological assessment, frequency of repeat 
testing, follow-up and screening protocol for alpha-1-antitrypsin deficiency. 
Subjects with homozygous (PiZ) AAT deficiency were more likely to: 1. have baseline and full pulmonary function 
testing including dynamic flow rates, static lung volumes, and gas transfer; 2. have more comprehensive assessment 
with high resolution computed tomography (HRCT) thorax and repeated radiological assessment (with annual chest 
radiography); 3. be followed-up routinely; and 4. have family members tested for alpha-1-antitrypsin deficiency. 
Testing remains limited for AAT deficiency and is mainly restricted to young patients with COPD. 
COPD assessment and management is influenced by the presence of AAT deficiency, which may reflect the poorer 
prognosis of such patients due to more rapid decline. Assessment and monitoring could be simplified to forced 
expired manoeuvres, although limited HRCT thorax and tests of gas transfer may prove more sensitive to 
progression of emphysema. Testing for AAT deficiency in the U.K. remains restricted, which will influence the 
detection rate for AAT deficiency. A wider policy of testing as advocated by the WHO will detect more patients and 
also influence our understanding of the natural history of the condition. 
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Introduction 
Alpha-1-antitrypsin (AAT) deficiency is one of the com- 
monest genetic deficiencies of Caucasians with an incidence 
as high as one in 1600 in Scandinavia (1). The protein is the 
major plasma inhibitor of serine proteinases and it is 
believed to play a critical role in the protection of the lung 
from proteolytic damage by the enzyme elastase released 
from activated neutrophils (2). The deficiency was first 
recognized in 1963 (3) and subsequent studies have 
confirmed its association with the early development of 
emphysema and bronchitis (4). Deficient subjects have an 
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increased risk for severe airflow obstruction and have an 
accelerated decline in lung function, especially if they 
smoke (5). 
In addition to the lung disease, deficient subjects develop 
neonatal jaundice which may be fatal (6), as well as 
cirrhosis and primary liver cancer in later life (7). 
Although AAT deficiency is relatively common, few of 
the subjects are identified unless population screening is 
undertaken (1,8). This is clearly of importance since early 
identification of the deficiency prior to the establishment of 
lung disease in particular can lead to a successful modifica- 
tion of lifestyle, especially with respect to smoking habit (9), 
which will have a major effect upon the long-term health 
cost burden. 
At a recent World Health Organization (WHO) meeting 
it was highlighted that only 5% of the deficient subjects in 
the U.K. have been identified by physician testing, as 
opposed to the predicted number by population screening 
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(10). The reasons for this were unknown but may relate to 
the possibility that most subjects remain reasonably healthy 
and thus do not present to health-care services. Alterna- 
tively, testing could be restricted to the wrong patient 
population. For instance, the first patients identified (3) 
were young with marked chronic obstructive pulmonary 
disease (COPD) and this has generally resulted in continued 
testing of mainly younger patients. Indeed, recent guide- 
lines on the management of COPD by the European 
Respiratory Society (ERS) (11) and the British Thoracic 
Society (BTS) (12) have emphasized testing for young 
patients. This restricted policy may have led to a predomi- 
nance of such patients in the American NIH registry of 
AAT deficiency (13) and continued testing bias. 
For these reasons the WHO has recommended much 
wider testing for AAT deficiency. Furthermore, the WHO 
has recognized that none of the COPD guidelines published 
by specialist societies specifically addressed the standards of 
care required for AAT deficiency. 
The purpose of the present study was to determine the 
current practice of U.K. hospital physicians, with an inter- 
est in respiratory disease, in the management of AAT 
deficiency. In particular we wished to determine whether 
management was different to that for non-deficient subjects 
with COPD. Finally we wished to clarify the current policy 
of the physicians for testing for AAT deficiency in advance 
of the publication of the BTS guidelines and the WHO 
report (10). 
ethods 
We administered a questionnaire (Appendix 1) to 88 con- 
sultant respiratory physicians who were based throughout 
the U.K. and selected at random at a single BTS meeting. 
Physicians were informed that the questionnaire was to 
determine how they believed an elderly patient (greater than 
50 years of age) with COPD should be managed. Once the 
answers had been obtained they were asked (with the same 
questions) if their policy would change if the patient were 
50 years of age or less. Finally, they were also asked if 
patients with the diagnosis of homozygous (PiZ) or hetero- 
zygous (PiMZ) AAT deficiency should be managed in the 
same or a different way. At the end of the questionnaire all 
physicians were asked who they felt should be tested for 
AAT deficiency. 
The questionnaire inquired into which investigations 
were routinely undertaken as a baseline to include pulmon- 
ary function tests, blood tests (i.e. full blood count and 
biochemical profile with liver function) and an electrocar- 
diograph. In addition, physicians were asked what further 
tests they would carry out including an oral steroid trial 
and inhaled steroid trial (and whether these influenced 
management), as well as which radiological assessment 
would be undertaken. Finally, we inquired about the usual 
frequency of repeat testing for monitoring disease progres- 
sion as well as the usual follow-up practice for the patient 
and whether this would be influenced by age or the AAT 
phenotype. 
The questionnaire also inquired about treatment giver 
routinely, including the use of bronchodilators, inhale< 
steroids and vaccination as well as the use of oral steroid: 
and antibiotics for acute exacerbations as generically 
defined (a worsening of any symptoms). 
Any differences between management policies for indi- 
vidual patient groups were compared by the chi-squared 
test, or Fisher’s test of exact probability when small num- 
bers (12~5) were encountered. P-values of less than 0.05 
were considered to be statistically significant. 
Eighty-eight randomly chosen respiratory physicians 
(which accounts for 20-25% of the physicians with an 
interest in respiratory medicine in the U.K.) were 
questioned at a single BTS meeting. The age of the 
physicians ranged from 34-65 years and there was an 
equal representation of teaching and district general 
hospital physicians. All physicians requested answered the 
questionnaire. 
The routine baseiine pulmonary function tests and radio- 
logical tests, including annual repeat testing, which U.K. 
respiratory physicians would routinely carry out are shown 
in Fig. 1. 
SPIROMETRY AND RADIOLOGY 
Ail respiratory physicians felt that all COPD patients 
should have baseline spirometry and a chest radiograph 
irrespective of age or AAT phenotype. Fewer physicians 
arrange full lung function tests (57 or 69%, depending on 
the age of patient), although 60% would assess lung func- 
tion fully in PiZ AAT deficient subjects. Serial peak flow 
monitoring to rule out asthma would be carried out by 
approximately 40% of physicians, although more (69%) 
would arrange this if the patient with COPD was young 
with normal AAT. Eightly-five per cent of physicians 
would carry out a steroid trial (75% with oral steroids 
and approximately 10% with inhaled steroids) prior to 
introducing steroid therapy. 
Only 2,3% of physicians would request high resolution 
computed tomography (HRCT) for patients iyith a diagno- 
sis of COPD unless they were young (28.4%) or had the 
PiMZ (13.6%) or PiZ phenotype for AAT deficiency 
(47.7%). 
ANNUAL REVIEW 
Few physicians carry out annual lung function testing, 
although more (35%) would do this for patients with PiZ 
AAT deficiency. Less than 20% of physicians would 
arrange for annual repeat chest radiograph unless the 
patient had PiZ AAT deficiency when a greater number 
(27.3%) felt this was important. 
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FIG. 1. The percentage of physicians who carry out routine baseline pulmonary function tests and radiological investiga- 
tions, including annual repeat testing, is shown on the vertical axis for patients with homozygous (PiZ) alpha-1-antitrypsin 
(AAT) deficiency (m), heterozygous (PiMZ) AAT deficiency @I), COPD patients ~50 years of age (0) and COPD patients 
>50 years of age (B). Statistical differences are shown for COPD patients >50 years of age, PiMZ and PiZ for AAT 
deficiency compared to COPD >50 years of age (*P<O.O5, **P<O.Ol and ***P<O.OOl). Statistical differences are also 
shown for heterozygotes and homozygotes for AAT deficiency compared to COPD 150 years of age (tWO.05, ttP<O.Ol 
and ‘ft’fP<O.OOl). Finally statistical differences are shown for heterozygotes compared to homozygotes for AAT deficiency 
($P<O.O5, QP<O.Ol and fj$P>O.OOl). 
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GENERAL INVESTIGATIONS AND 
MANAGEMENT 
In all groups approximately 85% of physicians would 
arrange a baseline full blood count, approximately 
70% a biochemical profile and approximately 55% an 
electrocardiograph. 
A small proportion of physicians (23.9%) would empiri- 
cally use inhaled steroids over the long term, independent of 
the results of a steroid trial or pulmonary function revers- 
ibility testing. The remainder would use long-term inhaled 
steroids only if there was a positive steroid trial. Treatment 
with inhaled bronchodilator therapy was based on the 
bronchodilator reversibility results by 42% of physicians 
but of the remainder, 42.1% would use a &-agonist agent 
alone and 11.4% would use combined bronchodilators 
irrespective of the reversibility testing. Influenza vacci- 
nation would be advised annually by 90.9% of physicians 
and 55.7% would advise pneumovax. Oral steroids and 
antibiotics would be used routinely by 71.6 and 78.4% of 
physicians, respectively, for any exacerbation of COPD that 
led to hospital admission. However if the exacerbation did 
not require admission, fewer (3l~X%) would use oral ster- 
oids (BO.001) but a similar proportion (70.4%) would use 
antibiotics (P=O.3). 
PATIENT FOLLOW-UP 
Most physicians (78%) would regularly review patients with 
PiZ AAT deficiency irrespective of the lung function. 
However more (90%) would follow-up these patients if the 
forced expiratory volume in 1 set (FEV,) were impaired to 
less than 50% predicted. Fewer physicians (42% if 
FEV,>70% predicted) would review patients who were 
heterozygous for AAT deficiency and the least (11% if the 
FEV,>70% predicted) would review COPD patients over 
50 years of age with normal AAT. However, there was 
again a tendency for a greater number to review each of the 
patient groups as lung function deteriorated (Fig. 2). The 
average interval between appointments was similar for each 
patient group (approximately 7 months; range l-12 
months). 
TESTING FOR AAT DEFICIENCY 
Most young patients (less than 50 years of age) with COPD 
would be tested for AAT deficiency by most physicians, 
whereas this would be infrequently carried out in elderly 
patients, those with bronchiectasis or patients with other 
causes of airflow obstruction including asthma. Testing is 
more likely to be carried out in patients with a family 
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FIG. 2. The percentage of physicians who would follow-up patients is shown on the vertical axis related to the patient 
subgroup by age, AAT phenotype and severity of airflow obstruction. Statistical differences are shown for COPD patients 
~50 years of age (U), heterozygotes (PiMZ) @) and homozygotes (PiZ) (R!) for AAT deficiency compared to COPD >50 
years of age (&) (*P<O,O5, **P<O~Ol and ***P<O.OOl). In addition statistical differences are shown for heterozygotes and 
homozygotes for AAT deficiency compared to COPD ~50 years of age (tP<O.05, ftP<O.Ol and tJ-tP<O,OOl), and finally 
statistical differences are shown for heterozygotes compared to homozygotes for AAT deficiency (fPc0.05, $$P<O.Ol and 
history of chronic lung disease or in family members of a 
known patient with AAT deficiency. These results are 
summarized in Table 1. 
TEACHING/DISTRICT GENERAL HOSPITAL 
BASED 
The answers to this questionnaire indicated no difference in 
patient management between consultants who were based 
in a teaching hospital and those based in a district general 
hospital (data not shown). 
Discussion 
This survey has shown that few patients with COPD are 
tested for AAT deficiency. This practice differs from that 
recommended by the WHO but the survey preceded publi- 
cation of the report (10). However, once identified the 
patients are investigated more extensively and most patients 
with PiZ AAT deficiency are kept under regular review 
TABLE 1. Current testing practice for AAT deficiency (per- 
centage of physicians who would test subjects in each 
category) 
Young (~50 years) emphysema/COPD 
Older emphysema/COPD 
Family history chronic lung disease 
Patients with bronchiectasis 
Other airflow obstruction, e.g. bronchiolitis 
Patients with asthma 
Family members of PiZ patients 
Family members of patients who are 
heterozygous for AAT deficiency 
88.6% 
10.2% 
44.3% 
20.5% 
15.9% 
2.3% 
98.9% 
53.4% 
although there are wide variations in management. 
Although consensus documents for the management of 
COPD have been published, the identification and manage- 
ment of patients with AAT deficiency have not been 
addressed specifically. At present a combined European 
Respiratory Society and American Thoracic Society Task 
Force has been established to develop specific guidelines 
but it will not report until the year 2000. It therefore seems 
appropriate to assess present views on the management of 
AAT deficiency and consider their validity in light of 
current practical and theoretical evidence. 
AAT deficiency is common and is associated with several 
disease conditions. The lung disease is more rapidly pro- 
gressive in smokers than subjects without deficiency and 
siblings also have a one in four chance of having deficiency. 
The pathogenic processes which result in the development 
and progression of the lung disease have been well defined 
(2) and this should lead to a different and perhaps more 
aggressive strategy in management of deficient subjects. 
BASELINE LUNG FUNCTION TESTING 
Optimal clinical practice would indicate that full lung 
function testing, including dynamic flow rates, static lung 
volumes and gas transfer, should all be assessed at baseline 
in order to document fully the physiological status of 
patients with COPD. The results of the present survey 
indicate that just over half of the physicians arrange this for 
COPD patients, although all would carry out dynamic flow 
rates in hne with the BTS guidelines (12). However more 
(approximately 80%) would obtain full lung function if the 
patient had AAT deficiency. This did not relate to whether 
the physician was practicing in a teaching hospital and is 
likely to reflect the unusual nature of the patient and a wish 
to document the patient more completely. 
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SERIAL PEAK FLOWS 
Of more interest is the use of serial peak expiratory flow 
rate (PEFR) monitoring at baseline. This practice enables 
marked diurnal variation to be identified suggesting a 
diagnosis of asthma. Significantly more clinicians assess this 
in young patients with COPD, indicating that asthma is 
either suspected more frequently in this group or that a 
different management strategy is believed to be more 
critical in younger patients who have both a longer life 
expectancy and may have greater life-style expectations. 
Surprisingly, PEFR monitoring was no more frequently 
used to assess patients with AAT deficiency than older 
COPD patients despite the general belief that such patients 
present at a young age. This difference in practice probably 
reflects a conceptional bias that AAT deficient subjects 
mainly develop fixed airflow obstruction. Studies have, 
however, shown that many such patients have symptoms 
suggestive of asthma (14) and reversible airflow obstruction 
(15). Indeed a recent study highlighted that lung function 
deterioration occurs in middle-aged non-smokers with 
AAT deficiency who have a history of wheezing (14). It 
would therefore seem appropriate to assess variability of 
airflow obstruction in all subjects with AAT deficiency and, 
where indicated, to treat appropriately. 
DISEASE MONITORING 
All physicians felt that an initial chest X-ray should be 
performed in all patients with COPD, even though this 
would not help in the assessment or diagnosis of generalized 
emphysema. It is likely that this is performed as a screening 
test for incidental lung lesions or possibly for identification 
of localized bullous disease as advocated in the guidelines 
(12). HRCT scan, however, has now become the best 
method for assessing the presence, extent and progression 
of emphysema, proving more effective than lung function 
testing (16,17). Despite this, HRCT is rarely performed 
although almost half the physicians felt that it should be 
performed in AAT deficiency. Recent studies, however, 
have indicated that limited HRCT (with appropriate reduc- 
tion in radiation dosage) provides a sensitive assessment of 
progression of emphysema in AAT deficiency (17). Despite 
this observation few physicians repeat the test, whereas 
chest X-rays, which are poorly sensitive, are repeated by 
one-third of physicians. 
On the other hand, full lung function is repeated annually 
in AAT deficiency by over one-third of all physicians. 
Current epidemiological data on progression of lung dis- 
ease are related to FEV, measurements alone which are 
simple (and hence cost-effective) and may reflect prognosis 
and hence referral for transplantation. However, tests of 
gas transfer are a more specific measure of the presence of 
emphysema and clearly relate to the changes on CT scan 
(18). It therefore remains possible that these more specific 
tests (though more expensive) may provide a clearer 
measure of progression. Clearly, further studies of the use 
of these tests in disease monitoring are indicated although 
preliminary data from our registry indicate that both 
HRCT and carbon monoxide transfer coefficient (KCO) 
(19) show significant changes over 12 months. 
The extent of disease monitoring should depend on the 
phenotype, smoking status and whether the patients have 
lung disease or not. Disease monitoring is of importance in 
determining prognosis in PiZ AAT deficient individuals 
with lung disease and annual follow-up is probably indi- 
cated and should, at present, include FEV, (which may 
decline exponentially). In addition PiZ AAT deficient indi- 
viduals without lung disease should undergo periodic moni- 
toring (for example every 2-3 years), even for non-smokers, 
as lung disease may develop later in life (14). Furthermore, 
such information will be critical in the understanding of the 
natural history of the deficiency. 
Heterozygote subjects are not thought to be at increased 
risk for the development of COPD. Thus at present it seems 
reasonable to monitor such patients in a similar way to 
non-deficient COPD patients. In the absence of lung disease 
(asymptomatic siblings) monitoring seems inappropriate 
except for research purposes. However, it is probably 
reasonable to check the phenotype of any spouse or partner 
to determine the risks of deficiency (PiZ) in any children. 
OTHER TESTS 
Of the other baseline investigations it is worth noting that 
only 70% of physicians perform blood tests that include 
liver function, even in subjects with AAT deficiency who are 
particularly susceptible to the development of cirrhosis and 
primary liver cancer (7). This may reflect a lack of aware- 
ness, the reduced tendency for lung and liver disease to 
co-exist (20) or a belief that the liver diseases cannot be 
influenced. Whereas this may be pathologically correct, 
alcohol avoidance and dietary modification can stabilize 
liver function thereby delaying the progression of liver 
failure leading to the need for transplantation. However, 
close monitoring in subjects with cirrhosis is necessary to 
identify hepatoma at an early stage when surgery may be 
possible. 
MANAGEMENT 
In general, patients with AAT deficiency are managed in 
the same way as other patients with COPD. Particular 
notice should be drawn to the use of inhaled steroids and 
antibiotics. The progression of disease in the presence of 
AAT deficiency is believed to be more rapid and dependent 
on tissue destruction or damage in close proximity to the 
migrating and activated neutrophil (2). The low concen- 
tration of AAT in the deficient subjects fails to control the 
area of connective tissue degradation by neutrophil 
enzymes adequately (21), leading to more extensive dam- 
age. Thus it would appear to be important to treat episodes 
of acute exacerbations associated with increased neutrophil 
influx both rapidly and effectively. In addition neutrophil 
traffic should, if possible, be modified even in the stable 
clinical state (2). With this in mind the use of inhaled 
steroids could be recommended empirically in these patients 
at present since such treatment has been shown to reduce 
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FIG. 3. The age range of patients identified as PiZ indi- 
viduals by the Protein Reference laboratory in Sheffield 
between 1995 and 1997 is shown. The vertical axis indi- 
cates the number identified in each decade of life. 
the chemotactic activity of airways secretions and increase 
the neutrophil elastase inhibitory capacity (22), both of 
which might be expected to reduce lung damage (2). 
Confirmation of the long-term elhcacy of such an approach 
clearly requires a controlled trial; however, as almost 25% 
of physicians already use such therapy empirically in COPD 
it seems reasonable to adopt this approach in AAT 
deficiency where the theoretical arguments for their use are 
stronger. 
Replacement therapy is theoretically even more likely to 
be beneficial by limiting the radius of lung damage caused 
by migrating neutrophils (21). Indeed, the recent NIH 
survey provides tantalizing evidence that replacement 
therapy may influence both FEV, decline in a subset of 
patients with moderate impairment as well as overall mor- 
tality (23). Unfortunately this was not a controlled trial, the 
non-treated patients were not well matched and treated 
patients would have been exposed to more health-care 
workers because of their weekly infusions. Clearly a con- 
trolled trial is urgently required to determine the efficacy 
and need for replacement therapy. 
AAT TESTING 
The attitudes to testing for AAT deficiency are worthy of 
specific comment. There remains a general belief amongst 
respiratory physicians and those surveyed here that testing 
should be generally limited to young people with COPD or 
those with a strong family history. This is in keeping with 
the recent recommendations by the (BTS) (12). However, it 
has long been known that bronchiectasis is present patho- 
logically (24) and is regularly seen on CT scans (25) of 
patients with deficiency. In addition, recent studies 
(14,15,26) have highlighted the presence of asthma or 
asthmatic symptoms in deficient subjects. Finally, it is 
known that the diagnosis can even be made in old age. 
Indeed: the age range of subjects identified over the past 3 
years at the protein reference laboratory in Sheffield is 
clearly wide (Fig. 3) and the peak age is the sixth decade. It 
therefore seems appropriate to emphasize the current WHO 
guidelines that all patients with COPD, all adult asthmatics 
and all patients with bronchiectasis should be tested (10). In 
addition, testing families of AAT deficient subjects (bot 
PiMZ and PiZ) will detect other deficient subjects an 
provide information necessary for appropriate geneti 
counselling. 
Although it could be argued that identification of mor 
elderly patients with AAT deficiency may not influenc 
their subsequent management, it should be rememberer 
that such subjects have increased mortality and, in particu 
lar, other family members at risk. Indeed, non-index case: 
are more likely to have better preserved lung function (271 
and hence will benefit more from the best clinical practice 
Ultimately the aim would be to identify young family 
members who can successfully be advised against starting 
smoking (9); thereby providing a long-term benefit to both 
themselves and the health-care services. 
Conclusion 
At present it seems appropriate to assess all AAT deficient 
subjects as fully as possible and advise them about family 
screening and lifestyle. Follow-up assessment should prob- 
ably be limited to forced expiratory manoeuvres at present 
with vital capacity although the role of limited HRCT and 
tests of gas transfer should be explored. Testing should be 
performed (initially) on an annual basis (except in hetero- 
zygotes with normal lungs, as such patients are unlikely to 
benefit from follow-up) until it is clear that progression is 
not rapid when a reduction in frequency of assessment can 
be instigated. All patients should be under the care of 
physicians with an interest in this deficiency and docu- 
mented on a national registry. A registry will be of major 
importance for learning more about the natural history of 
the disease and in particular why only a portion are 
susceptible to the liver or lung manifestation, In addition a 
registry will provide the core information critical for the 
design and implementation of careful intervention studies. 
At present, a U.K. registry has been established with 
information on over 200 patients. An international com- 
mittee of 12 national registries has been established with a 
common database in Sweden, which makes the likelihood 
of controlled trials a realistic option. 
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Appendix A 
Consultant 
Hospital 
City 
Country 
Teaching/DGH 
Date questionnaire 
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INVESTIGATION AND MANAGEMENT OF COPD 
If a patient presenfs as an in-patient OY in youv clinic as COPD 
Tick and indicate how often you would repeat the tests, e.g. 6-monthly, mark 6; yearly, mark 12 etc. 
1. Lung function 
Basic spirometry 
Flow volume curves 
Static lung volumes 
Gas transfer factor 
Reversibility &agonist (if indicated) 
Reversibility anticholinergic 
Reversibility to both on separate days 
Serial peak flows 
2. Diagnostic tests 
Full blood count 
ESR/plasma viscosity 
Biochemistry profile 
Thyroid function 
Immunoglobulins 
Auto-antibodies 
Complement 
Cilia studies 
Sweat tests 
3. Radiology 
PA CXR 
Left lateral CXR 
CT chest 
if Yes, is it a HRCT? 
is it in inspiration and expiration? 
MRI chest 
4. Further tests 
Formal oral steroid trial 
Inhaled steroid trial 
ECG 
Exercise tests 
5. Treatment -which bronchodilator do you routinely use first? 
&agonist first 
Anticholinergic first 
Combination first 
Based on bronchodilator studies 
Theophylline 
Inhaled steroids empirically 
Inhaled steroids based on steroid trial 
Advise yearly flu vaccinations 
Advise pneumovax 
Age >50 
NO Repeat 
q q 
c7 0 
El 0 
q q 
3 El 
0 El 
q 0 
0 cl 
Age >50 
No Repeat 
3 q 
0 0 
c7 cl 
3 ;I 
0 0 
0 3 
0 El 
El 0 
0 0 
Age >50 
No 
0 
3 
0 
3 
0 
0 
Age >50 Age ~50 
Yes No Yes No 
0 L? 0 0 
0 Q 0 3 
0 0 3 9 
0 0 0 0 
Age >50 Age ~50 
Yes No Yes No 
0 0 0 3 
0 0 !l 3 
El 0 0 q 
0 rl cl 0 
1 rl 0 3 
cl q 53 3 
0 0 7 q 
0 0 0 0 
Ll 0 q 3 
Repeat 
n 
0 
0 
Age ~50 
No Repeat 
9 0 
0 II 
3 ci 
II cl 
0 0 
3 cl 
CI 3 
0 0 
Age <SO 
No Repeat 
0 0 
cl 0 
El 0 
3 0 
7 cl 
0 q 
0 3 
0 !I 
q 0 
Age ~50 
No Repeat 
cl 3 
n 9 
q 0 
0 
II 
3 a 
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6. Treatment continued 
As out-patient use oral steroids for all exacerbations 
As out-patient use antibiotics for all exacerbations 
As in-patient use oral steroids for all exacerbations 
As in-patient use antibiotics for all exacerbations 
7. Medical follow-up arrangements 
Patients on home nebulised bronchodilators 
If Yes, when do you see them? 
Patients on LTOT 
If Yes, when do you see them? 
Patients with severe airflow obstruction not yet needing home 
neb. bronchodilators or LTOT 
(FEVi ~35% predicted) 
If Yes, when do you see them? 
Patients with moderate airflow obstruction 
FEV, 35-60% predicted) 
If Yes, when do you see them? 
Patients with mild airflow obstruction 
(FEV, >60% predicted) 
If Yes, when do you see them? 
All emergency admissions? 
If Yes, when do you see them? 
Age >50 Age ~50 
Yes No Yes No 
q q q q 
q 3 cl q 
q q q 3 
rl 3 q q 
Age >50 
Yes No 
q 0 
months 
0 n 
months 
q 0 
months 
0 q 
months 
0 0 
months 
2 El 
months 
Age <50 
Yes No 
q 3 
1 3 
II q 
u 3 
J q 
q q 
INVESTIGATION AND MANAGEMENT OF a,AT DEFICIENCY 
Homozygaus [PiZ) and heteuozygous [MZ) 
Tick and indicate how often you would repeat the tests, e.g. 6-monthly, mark 6; yearly, mark 12 etc. 
1. Lung function 
Basic spirometry 
Flow volume curves 
Static lung volumes 
Gas transfer factor 
Reversibility /&agonist (if indicated) 
Reversibility anticholinergic 
Reversibility to both on separate days 
Serial peak flows 
2. Diagnostic tests 
Full blood count 
ESR/plasma viscosity 
Biochemistry profile 
Thyroid function 
Immunoglobulins 
Auto-antibodies 
Complement 
Ciiia studies 
Sweat tests 
Yes 
3 
0 
n 
El 
q 
@ 
0 
rl 
Yes 
0 
0 
0 
1 
3 
0 
7 
q 
0 
PiZ 
No 
3 
0 
0 
0 
0 
2 
0 
rl 
PiZ 
No 
0 
3 
0 
u 
u 
q 
u 
q 
3 
Repeat Yes 
[7 q 
q q 
q ? 
q q 
0 T 
q q 
0 q 
3 q 
Repeat Yes 
Ll 7 
q q 
q q 
7 q 
q q 
P 1 
q q 
? 3 
q n 
PiMZ 
No Repeat 
q q 
!I 3 
El q 
q n 
q q 
q u 
7 q 
q q 
PiMZ 
No Repeat 
q q 
q ? 
q c1 
7 q 
q 3 
II 0 
q 0 
q 0 
q 0 
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3. Radiology 
PA CXR 
Left lateral CXR 
CT Chest 
if Yes, is it a HRCT? 
is it in inspiration and expiration? 
MRI chest 
4. Further tests 
Formal oral steroid trial 
Inhaled steroid trial 
ECG 
Exercise tests 
5. Treatment-which bronchodilator do you routinely use first? 
/&-agonist first 
Anticholinergic first 
Combination first 
Based on bronchodilator studies 
Theophylline 
Inhaled steroids empirically 
Inhaled steroids based on steroid trial 
Advise yearly flu vaccinations 
Advise pneumovax 
6. Treatment continued 
As outpatient use oral steroids for all exacerbations 
As outpatient use antibiotics for all exacerbations 
As inpatient use oral steroids for all exacerbations 
As inpatient use antibiotics for all exacerbations 
7. Medical follow-up 
Regular follow up? 
If Yes, how often do you see them? 
8. Would you carry out family studies? 
PiZ a,AT deficient patients 
PiMZ a,AT deficient patients 
9. Would you screen the following for a,AT deficiency? 
COPD ~50 years 
All COPD 
Family history of chronic lung disease 
Asthma 
Bronchiectasis 
Other airflow obstruction (bronchiolitis etc.) 
PiZ 
Yes No Repeat 
3 C 0 
0 3 0 
Ll G @ 
0 0 
0 I3 
1 e G 
PiMZ 
Yes No Repea 
J Ll e 
0 0 3 
G 9 J 
3 c 
0 5 
a u 0 
PiZ PiMZ 
Yes No Yes No 
0 0 3 3 
0 @ 17 0 
CI ? 17 J 
3 q 17 Ll 
PiZ 
Yes No 
cl G 
0 0 
0 0 
n q 
q 0 
0 n 
q 0 
0 0 
0 G 
PiZ 
Yes No 
0 0 
0 0 
0 0 
q 0 
PiZ 
Yes No 
G Li 
Yes No 
0 J 
3 3 
PiMZ 
Yes No 
3 3 
I7 c 
0 J 
2 Ll 
J 17 
0 rl 
J J 
J G 
G J 
PiMZ 
Yes No 
J I7 
0 G 
J 2 
Ll 0 
PiMZ 
Yes No 
2 3 
months 
